A subset of phagocytes including inflammatory monocytes in blood migrate and give rise to macrophages in inflammatory tissues which generated the idea that blood monocytes are the therapeutic targets for drug delivery. Fc gamma receptor I (CD64) is a membrane receptor for the Fc region of immunoglobulin G, primarily expressed on monocyte-lineage, and H22 a monoclonal antibody for human CD64 had shown rapid blood monocyte binding and occupation in clinical studies. Small interfering RNA-mediated gene silencing as a therapeutic has been proposed and is a promising strategy in terms of its "knock-down" ability on the target gene prior to translation. However, its instability and off-targeting effect must be overcome for success in clinical studies. In this study, we developed a non-viral delivery system composed of oligo-nona-arginine (9R) and anti-human CD64 single chain antibodies (H22) for human monocyte-specific siRNA delivery. A targeted and efficient siRNA delivery mediated by anti-CD64 scFv-9R was observed in CD64 positive human leukemia cells, THP-1. With primary human blood cells, anti-CD64 scFv-9R mediated gene silencing was quantitatively confirmed representing blood monocyte selective gene delivery. These results demonstrate the potential of anti-CD64 scFv-9R mediated siRNA delivery for the treatment of human inflammatory diseases via blood monocytes gene delivery.
Mononuclear phagocytes are primary components of the immune system, and are involved with body homeostasis and immunological effector functions such as red blood cell clearance, cytokine release and foreign phagocytosis. Mononuclear phagocytes are considered a hindrance to drug delivery systems, as the actions of phagocyte often limit drug efficacy, mainly kupffer cells in the liver sequester and internalize administered nanoparticles and remove 1 . However, a subset of blood monocytes migrate to and accumulate in diseased areas and inflammatory tissues. This observations inspired another perspective, one in which the blood monocytes could be used as therapeutic targets for drug delivery. Inflammatory-monocytes, including Ly6c-high monocytes in mice and CD14-high monocytes in human are the main subsets known for CCR2-mediated accumulation in sites of inflammation such as infarcted cardiac 2 , adipose tissues 3 , brain myelitis 4 and tumors 5 . Some papers have reported that cancer cell metastasis is also supported by inflammatory-monocytes 6 . Tissue accumulated monocytes can ultimately differentiate into inflammatory-macrophages to activate or modulate the inflammation. Consistent with this observation, siRNA-mediated chemokine receptor (CCR2) reduction in blood monocytes reduced tissue monocyte and macrophage accumulation resulting in lower levels of tissue damage and reduced-lesion sizes in mice disease models 7 . Recently even the tumor targeting effect of carbon nanotubes has been shown to be partially mediated and enhanced by inflammatory-monocytes 8 , consequently suggesting the therapeutic potential of blood monocytes-targeted and -mediated drug delivery for human diseases.
Small interfering RNAs are short, 21-24 nucleotide RNA fragments that regulate gene expression, primarily in the cytosol. Compared with antibodies and synthetic drugs, siRNAs are capable of "knocking down" target genes with high specificity before translation 9 . Like other drugs siRNAs require a delivery system for improved efficacy and reduced side effects in vivo. Over the past few decades targeted siRNA delivery systems have been developed depending on targeting moieties such as peptides 10 , antibodies 11 , natural molecules 12 and aptamers 13 . Single chain antibody (scFv), the antigen binding portion of antibody retains its high antigen binding affinity as whole antibody with smaller size and have been applied for targeted siRNA delivery. In papers of anti-CD7 scFv . The Fc gamma receptor family encompasses membrane glycoprotein receptor for the Fc region of immunoglobulin G and distributed on diverse type of cells, from immune cells to endothelial, epithelial cells. Human Fc gamma receptor I (CD64) expression is primarily on monocytes and cells of macrophage lineages 17, 18 . The H22, a monoclonal antibody targeting human CD64 have been applied for immunotoxins ablating CD64-positive monocytic leukemia 19 , and phase I clinical studies showed rapid monocyte binding of H22 in circulation 20, 21 . In this study, we investigate CD64-targeted siRNA delivery for human blood monocytes gene silencing. We conjugated nucleic acid binding nona-arginine peptide with an anti-human CD64 single chain antibody (H22). Anti-CD64 scFv-9R showed target-receptor mediated siRNA delivery and gene silencing in a human monocytic cell line (THP-1). In human peripheral blood cells (PBMCs), anti-CD64 scFv-9R showed monocytes-selective uptake and gene silencing without significant toxicity ex vivo. With a human monocyte engrafted mouse, scFv-9R/siRNA complex demonstrated human monocyte-targeted delivery in vivo, and collectively demonstrated the potential of CD64 targeted scFv-9R for blood monocyte siRNA delivery in human inflammatory disease.
Results
Schematic illustration of CD64-targeted siRNA delivery system. It has been reported that the monoclonal antibody for human CD64, H22 binds to different epitopes from IgG binding, representing target binding in the presence of serum IgG 22 , and H22 has shown rapid blood monocyte binding in phase I clinical trials 20, 21 . Additionally toxins conjugated with H22 were efficiently internalized into CD64 positive leukemia cells and induced cancer cell apoptosis 23 . Based on these studies, we developed a CD64-targeted non-viral carrier consisting of a single chain antibody of H22 (anti-CD64 scFv) and 9-mer oligo-D-arginine (9R) as shown in Fig. 1a , having triple benefits of target specificity, gene stabilization and cell penetrating efficiency. For construction of the anti-CD64 scFv-expressing vector, the gene sequence encoding anti-CD64 scFv was cloned into pET21a. Anti-CD64 scFv contains a signal peptide (pelB) for periplasmic localization, which facilitates protein folding, linker sequence (GlySer 4 ) 3 and cysteine to create a disulfide bond with the terminal cysteine of oligo-nona-D-arginine (Fig. 1b) . Oligo-arginine has been widely used for protein 24, 25 and gene delivery 10, 26, 27 . In particular, D-form oligo-arginine has been reported to be more effective in improving gene transfection efficiency and in vivo stability than L-form. Reducible polymers based on the D-form oligo-arginine have shown significantly improved transfection efficiency compared with PEI and lipofectamine 28 . As described in reference 14 , oligo-D-arginine with an (Npys) cysteine residue was incubated with anti-CD64 scFv in a low pH phosphate buffer for conjugation and dialyzed to remove unconjugated oligo-arginine (MWCO; 12-14,000 Da) (Fig. 1c) .
Characterization and functionality of purified anti-CD64 scFv and anti-CD64 scFv-9R conjugate. The anti-CD64 scFv expressed in a bacterial system (BL21 (DE3)) and purified using affinity chromatography provided a single band around 26 kDa in SDS-PAGE. The western blot result stained with an anti-histidine tag antibody showed the same band location as SDS-PAGE (Fig. 2a) . After oligo arginine conjugation, anti-CD64 scFv-9R conjugate showed a single band at the expected position in SDS-PAGE and The conjugation efficiency was ~77% as quantified using a free thiol quantification kit (Fig. S1b) . The functionality of anti-CD64 scFv was tested by measuring competitive binding with a commercial human CD64 antibody in CD64 positive THP-1 and CD64 negative MDA-MB-231 cells. As shown in Fig. 2b , THP-1 cells pre-incubated with anti-CD64 scFv (black thick line) demonstrated reduced commercial CD64 antibody (FITC) binding, representing that anti-CD64 scFv competes with commercial CD64 antibody. On the other hand, no competitive binding was observed between anti-CD64 scFv and other antibodies against CD14 and CCR2 in THP-1 cells. CD64 negative MDA-MB-231 cells did not show binding affinities for anti-CD64 scFv and commercial CD64 antibody. In the siRNA retardation study, anti-CD64 scFv-9R conjugate retarded the siRNA in the N/P ratio above 4 in contrast to anti-CD64 scFv (Fig. 2c) . The size of anti-CD64 scFv-9R/siRNA was analyzed with transmission electron microscopy ( Fig. 2d) and DLS nano-size distribution (Fig. 2e) .
Anti-CD64 scFv-9R mediated siRNA delivery into THP-1. To examine anti-CD64 scFv-9R mediated siRNA delivery in CD64 positive cells, we incubated the anti-CD64 scFv-9R/siRNA complex with human monocytic leukemia cell THP-1. After an incubation period of 30 min-1 hour, siRNA complexed with anti-CD64 scFv-9R bound or internalized in THP-1 cells with ~25 mean fluorescence intensity (MFI) fold change than that of naked siRNA or anti-CD64 scFv complexed siRNA. In the presence of free anti-CD64 scFv, anti-CD64 scFv-9R/siRNA complex showed decreased fluorescence intensity, means 'target receptor-mediated' and 'scFv mediated' cell association (Fig. 3a) . In a longer time period (13 hours), anti-CD64 scFv-9R increased the cellular uptake of siRNA, with a mean fluorescence intensity 2 to 5 times greater than that of naked siRNA depending on the amount of anti-CD64 scFv-9R and siRNA (Fig. 3b) . To confirm its CD64-target specificity, THP-1 and MDA-MB-231 (CD64 negative) were treated with anti-CD64 scFv-9R/siRNA complex. THP-1 cells internalized anti-CD64 scFv-9R/siRNA though lipofectamine2000/siRNA showed lower internalization. However MDA-MB-231 did not internalize anti-CD64 scFv-9R/siRNA despite the high uptake of lipofectamine2000/ siRNA (Fig. 3c ). In addition, CHO-K1 cells (hamster ovary cells) were transfected with human CD64-expressing vector (CMV-promoter, origene) and treated with scFv-9R/siRNA complex. Blood monocyte specific uptake and gene silencing of anti-CD64 scFv-9R/siRNA in human peripheral blood mononuclear cells. In human blood, monocytes are known to express CD64, and human monocytes can be classified based on surface CD14 and CD16 expression. Human CD14-high monocytes are inflammatory-monocytes complement to Ly6c-high monocytes in mice 29 , accumulate in inflammatory sites migrated from spleen 2 or bone marrow. To confirm monocyte specific siRNA delivery, we used human peripheral blood mononuclear cells (PBMC). In PBMCs, CD14 monocytes expressed CD64 on its surface, but not on the others (Fig. 4b) . To test blood monocyte-targeted siRNA delivery, we incubated PBMCs with the anti-CD64 scFv-9R/siRNA complex. After 11-12 hours (4 hours of treat and additional 7-8 hours), the CD14 positive cell population took up anti-CD64 scFv-9R/siRNA complex and CD14 negative cell population did not. For further analysis, treated PBMCs were gated for cell lineage markers (CD14, CD3 and CD19). As shown in Fig. 4c , most of CD14 (+ ) cells took up anti-CD64 scFv-9R/siRNA complex, and very few CD3 (+ ) T cells and CD19 (+ ) B cells did. Total lymphocytes also did not take up anti-CD64 scFv-9R/siRNA complex. Consistent with FACS results, CD14 (+ ) cells took up anti-CD64 scFv 9R/siRNA complex in confocal microscopy imaging (Fig. 4d, Fig. S4 ). To examine gene silencing effects, CD14 and SSC based FACS sorting carried out (Fig. S5 ). Sorted CD14 (+ ) monocytes and lymphocytes were treated with the anti-CD64 scFv-9R/siCypB complex, and cyclophilin B mRNA was measured using RT-PCR. In comparison with lymphocytes, cyclophilin B mRNA was reduced in CD14 (+ ) cells only (~50% to control group), consistent with FACS analysis (Fig. 4e , **p < 0.01). In contrast, other groups showed similar cyclophilin B mRNA levels between CD14 (+ ) cells and lymphocytes (~80 to 90% to control groups). To measure gene silencing effect in protein level, cyclophilin B protein level was identified using western blots. As shown in Fig. 4f , scFv-9R/siCypB reduced cyclophilin B protein in CD14 (+ ) monocytes specifically. In contrast, Lipofectamine2000/siCypB complex reduced cyclophiln B protein both in lymphocytes and CD14 (+ ) monocytes. The siRNA for human CD45 (protein tyrosine phosphatase) was used 7 for surface protein level silencing test and CD14 and SSC based gating strategy confirmed that CD14 (+ ) monocytes specific reduction in surface CD45 (*p < 0.05, mean fluorescence intensity value was ~80% compared to naked siCD45 group and anti-CD64 scFv-9R/siLuci group), but lymphocytes did not exhibit even a slight decrease in surface CD45 expression (Fig. S3) .
Toxicity of anti-CD64 scFv-9R/siRNA complex on human PBMC. To test for cytotoxicity, anti-CD64 scFv-9R/siRNA complex treated PBMCs were stained with Annexin V (PE) and analyzed. In comparison with non-treated groups, and only siRNA treated groups, the anti-CD64 scFv-9R/siRNA complex treated group did not exhibit a significant change in Annexin V staining, indicating that anti-CD64 scFv-9R doesn't have significant toxicity. As a positive control, heat-shocked PBMCs showed substantial change in Annexin V staining (Fig. 5a) . Additional cell viability test was performed with MTT assay. As shown in Fig. 5b , sorted CD14 (+ ) monocytes and lymphocytes were treated with scFv-9R/siRNA complex in the same concentration as the knock-down experiments. Compared with other groups, scFv-9R/siRNA complex showed no significant toxicity. To examine immune response, inflammatory gene mRNA levels were measured 30, 31 . The naked siRNA treated groups showed slight TNF-alpha down regulation and IFN-gamma, IFN-beta, IL-6 up regulation, thought to be the TLR signaling mediated response as previously reported 32 . The scFv-9R complexed siRNAs compromised the siRNA mediated inflammatory gene induction and is due to the sequestering of the scFv-9R complexed siRNAs inside in higher N/P ratio (Fig. 5c ). These results indicate that the anti-CD64 scFv-9R/siRNA complex has mild toxicity in the indicated amount, and masking the siRNA's natural immune response.
In vivo human monocyte targeting effect of anti-CD64 scFv-9R/siRNA complex. To test in vivo targeting effect of scFv-9R/siRNA complex on human monocytes, human CD14 (+ ) monocyte-engrafted NOD-scid mice (5-7.5 × 10 5 cells per mouse) were injected with scFv-9R/siRNA complex intravenously and after 1-2 hours, total blood cells were analyzed for siRNA uptake. As shown in Fig. 6b , the complex of scFv-9R with siRNA was taken-up by human monocytes (human CD45 staining). In contrast, mouse monocytes (mouse CD45 staining, FSC) showed no-uptake. As shown in Fig. 6a , scFv-9R/siRNA complex was cleared from blood after 2 hours 33, 34 (Fig. 6a) . 
Discussion
Many papers proved that subsets of monocytes are the source of disease accumulating macrophages [2] [3] [4] [5] , suggesting that blood circulating monocytes are appropriate targets for disease-targeted drug delivery. Phagocyte-targeted drug delivery, especially for monocyte and macrophage lineage have demonstrated its therapeutic effect in animal models 7, 30 , and potential human clinical application. In our previous work, polymerization of D-form oligo-arginine with terminal cysteine residues (rPOA) improved its gene transfection ability for both siRNA & plasmid DNA. Despite high transfection efficiency, its non-target specificity limits local in vivo applications 35, 36 . With the theory of human blood monocytes as drug delivery targets, we developed a non-viral siRNA delivery system based on a single chain antibody and oligo-arginine. Target receptor human CD64, a monocyte lineage-specific expression improves its target specificity. Some papers reported CD64 expression is elevated on circulating monocyte from patient with inflammatory disease and its expression is IFN-gamma signaling mediated 37, 38 resulting in inducible inflammatory conditions, and also IFN-gamma is known for its role in M1 macrophage polarization. For the goal of targeting, we employed H22 (scFv), anti-human CD64 antibody as a targeting moiety. H22 is different from IgG for Fc receptor binding in terms of binding epitope and Fc gamma receptor I (CD64) specificity rather than other type of Fc receptors (CD32, CD16) 22 , and this has been applied for the development of immunotoxins targeting CD64-positive human myeloid leukemia in previous studies 19, 23, 39, 40 . In this study, anti-CD64 scFv-9R/siRNA complexes were characterized for their target receptor-mediated cell binding and uptake, and lipofectamine comparable gene silencing efficacy in THP-1. Experiments with human PBMCs demonstrates blood monocyte specific uptake and gene silencing ex vivo and human monocyte-targeting effect in vivo. However we found mild silencing effect on protein levels which may be attributed to the non-proliferative or quiescent state of monocyte ex vivo and limited endosome escape of oligo-arginine. Generally for non-proliferative primary cell gene delivery, investigators add growth factors inducing proliferation such as IL-13, PHA in case of human T cells 14, 41 . Meanwhile, siRNA mediated gene silencing in mouse blood monocytes was not significant compared with other phagocytic cells 7 . Furthermore, CpG ligand mediated siRNA delivery did not reduce the target gene in the human monocyte even with a high uptake 42 , suggesting that monocytes are cells relatively harder to transfect than other phagocytes and have their own endosomal degradation and clearance mechanism. In terms of clinical application, applying targeting moiety for human receptor improves its potency as a drug, jumping the cross-species reactivity problem, but it doesn't exclude the need for animal studies such as target specificity and efficacy in vivo. Humanized mice is an existing animal model for human immune cell study in vivo, and genetic engineering technologies have developed mouse strains more suitable for human immune system simulation. A recent paper reported tumor accumulation of human macrophages in a cancer cell grafted to TG mice as the same as in a human patient 43 . However those generations do not reflect whole human inflammatory disease pathology such as disease accumulation of phagocytes [43] [44] [45] in inflammation. Collectively, our data demonstrates the CD64-targeted siRNA delivery as a potent system for human blood monocyte gene delivery.
Materials and Methods
Vector construction. An 800 base pair sequence-encoding anti-human CD64 scFv with a C-terminal cysteine residue and a 6x His-tag was synthesized and cloned (Incorporation Bioneer) between xbaI and NotI restriction sites of the pET21a vector (Novagen, Madison, WI) for bacterial expression.
SiRNAs. Luciferase siRNA conjugated with FITC was synthesized and purchased from ST Pharm. Co. Ltd.
SiRNAs for cyclophilin B (siCypB), CD45 (siCD45), and luciferase (siLuci) were purchased from Dharmacon.
Cell culture. THP-1 and MDA-MB 231 were purchased from KCLB (Korea Cell Line Bank, Korea). THP-1 cells were cultured in RPMI1640 (Welgin, Korea; FBS 10%, penicillin 1%) and MDA-MB 231 cells were cultured in DMEM high glucose (Welgin, Korea; FBS 10%, penicillin 1%). THP-1 cells were passaged to a cell density of 1 × 10 5 cells/ml.
Human peripheral blood mononuclear cell. For human peripheral blood cell culture, PBMCs were purchased from StemCell or Lonza and cultured in RPMI1640 (Welgin, Korea; FBS 10%, penicillin 1%).
Protein expression. For anti-CD64 scFv expression, BL21 (DE3) cells (Novagen, Madison, WI) inoculated with anti-CD64 scFv pET21a vector were cultured in 50 ml of ampicillin containing LB medium at 37 °C. After 4 hours cells were cultured in 500 ml of ampicillin containing LB medium. When O.D 600nm reached 0.3-0.5, 1 mM IPTG was added and cells were induced for 16 hours at 26 °C. Induced cells were collected using a centrifuge at 480 g, and pellets were re-suspended in a lysis buffer (pH 8.0) and then sonicated. Soluble protein solutions were collected using a centrifuge at 27,500 g, and the resultant solutions were filtered using a 0.45 μ m filter.
Affinity chromatography purification. Soluble protein solution was loaded onto nickel-agarose resin (Qiagen)-charged column and washed with 10 volume equivalents of washing buffer (25 mM imidazole). Resin bound proteins were eluted with elution buffer (250 mM imidazole) and dialyzed with a dialysis membrane (Spectrum laboratories, CA; MWCO = 12-14,000 Da) using phosphate buffered saline (PBS; pH 7.4). and resuspended in a 0.1 M potassium phosphate buffer (pH 5.6). Phosphate buffer-dialyzed anti-CD64 scFv (0.5 mg/ml) was mixed with 9-D arginine in a molar ratio of 1:10, incubated for 4 hours in a dark room with gently stirred. After 4 hours of incubation, the solution was dialyzed to remove un-conjugated D-9 arginine (MWCO = 12-14,000 Da).
SDS-PAGE
Retardation assay. The siLuci (40 pmol) was mixed with anti-CD64 scFv or anti-CD64 scFv-9R in diverse N/P ratios and incubated for 15-20 min at room temperature. Samples were loaded into a 2% agarose gel and electrophoresed, and detection was performed using a Kodak image station.
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Conjugation efficiency. Oligo-arginine conjugation efficiency was quantified with free-thiol quantification kit (M30550, Invitrogen). Simply, free thiol group of scFv, scFv-9R was quantified and relative ratio and conjugation efficiency were calculated. Anti-CD64 scFv-9R mediated siRNA delivery with human peripheral blood mononuclear cell (PBMC). After thawing and passaging, the 1-2 × 10 6 PBMCs were seeded in 24-well plates with RPMI1640 media (FBS 10%, penicillin 1%). After 22-24 hours, 110 pmol to 150 pmol of siLuci (FITC) complexed with anti-CD64 scFv-9R prepared in serum free media were mixed with PBMCs. After 4 hours of incubation, media was replaced with serum-containing media and incubated for an additional 7-9 hours. The PBMCs were stained with anti-CD14 antibody (PE) or anti-CD3 antibody (PE), as well as anti-CD19 antibody (PE) for flowcytometry analysis. For RT-PCR, fluorescence associated cell sorting (FACS) sorted 2 × 10 5 CD14 (+ ) cells and lymphocytes were seeded in 24 well plate and treated with anti-CD64 scFv-9R/siCypB complex (110 pmol, N/P ratio = 4). After 4 hours of incubation, media was replaced with serum-containing media and incubated for an additional 20-22 hours for total RNA isolation. For western blot, 2 × 10 6 PBMCs/well (24 well plate) were seeded and treated with anti-CD64 scFv-9R/siRNA complex. 30 hours after treat, cells were stained anti-CD14 antibody (PE) and sorted with FACS Aria and sorted cells were used for western blot sampling. For the surface CD45 silencing test, total PBMCs were co-stained with anti-CD45 antibody (PerCP Cy5.5), anti-CD14 antibody (FITC), and monocytes, lymphocytes were gated and analyzed for surface CD45 measurement.
Anti
Annexin V assay. Pre-seeded PBMCs (2 × 10 MTT assay. The FACS sorted 2 × 10 5 of CD14 (+ ) monocytes and lymphocytes were seeded in 24 well plate and treated with anti-CD64 scFv-9R/siRNA complex (siRNA 150 pmol, N/P ratio 4). MTT solution was added after 24 hours and colorimetric analysis was performed.
Immune response assay. Pre-seeded PBMCs (2 × 10 6 cells/well) were treated with naked siLuci (150 pmol) or siLuci complexed with anti-CD64 scFv-9R (N/P ratio = 4 and 6). After 24 hours total RNA was isolated and the mRNA levels were measured and normalized by beta-actin mRNA.
In vivo human monocyte targeting effect. The 5-7 weeks aged NOD-scid (Jackson laboratory) mice were engrafted with FACS sorted human CD14 (+ ) monocytes (5-7.5 × 10 5 cells per mouse) by intravenous injection. After 1-2 hours, anti-CD64 scFv-9R/siRNA complexes (siRNA (FITC) 500 pmol, N/P ratio 4) were injected intravenously and incubated for additional 1-2 hours in dark. Total blood was harvested from mouse heart and lysed with red blood cell lysis buffer (Sigma Aldrich) and stained with mouse, human CD45 antibody (PerCP-Cy5.5) for flowcytometry analysis. The blood monocytes were indicated with forward scattering (FSC) and CD45 staining. All animal experimental procedures with NOD-scid mice were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Hanyang University (HY-IACUC-16-0126) and was performed in accordance with the relevant guidelines. The mice were housed under specific pathogen free conditions.
Blood profile. The NOD-scid (Jackson laboratory) mice were engrafted with FACS sorted human CD14 (+ ) monocytes (5-7.5 × 10 5 cells per mouse) and injected with scFv-9R/siRNA complex (siRNA (Cy5.5) 500 pmol, N/P ratio 4). At each time points, 30-50 ul of blood was harvested from orbital vein and incubated 30 min for serum isolation. Serum was 3 times diluted in PBS and detected for Cy5.5 (excitation: 695 nm, emission: 720 nm). Flowcytometry analysis. All treated replicates were assembled and prepared in one tube and performed with BD FACS Calibur (BD biosciences, San Diego, CA) and analyzed with CellQuest Software (BD Pharmingen, San Jose, CA).
